🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Jefferies Group’s CRSP Holdings & Trades

First Buy
Q4 2022
Duration Held
5 Quarters
Largest Add
Q2 2026
+24,001 Shares
Current Position
24,001 Shares
$1.31 M Value

Jefferies Group's CRSP Position Overview

Jefferies Group (via Jefferies Financial Group Inc.) currently holds 24,001 shares of CRISPR Therapeutics AG (CRSP) worth $1.31 M, representing 0.01% of the portfolio. First purchased in 2022-Q4, this short-term holding has been held for 5 quarters.

Based on 13F filings, Jefferies Group has maintained this position in CRSP for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2026, adding 24,001 shares. Largest reduction occurred in Q1 2023, reducing 4,271 shares.

Analysis based on 13F filings available since 2013 Q2

Jefferies Group's CRISPR Therapeutics (CRSP) Holding Value Over Time

Track share changes against reported price movement

Quarterly CRISPR Therapeutics (CRSP) Trades by Jefferies Group

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2026 +24,001 New Buy 24,001 $54.54
Q1 2024 -1 Sold Out 0 $0.00
Q4 2023 +1 New Buy 1 $63.00
Q1 2023 -4,271 Sold Out 0 $0.00
Q4 2022 +4,271 New Buy 4,271 $40.65

Jefferies Group's CRISPR Therapeutics Investment FAQs

Jefferies Group first purchased CRISPR Therapeutics AG (CRSP) in Q4 2022, acquiring 4,271 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Jefferies Group has held CRISPR Therapeutics AG (CRSP) for 5 quarters since Q4 2022.

Jefferies Group's largest addition to CRISPR Therapeutics AG (CRSP) was in Q2 2026, adding 24,001 shares worth $1.31 M.

According to the latest 13F filing for Q2 2026, Jefferies Group's firm, Jefferies Financial Group Inc., owns 24,001 shares of CRISPR Therapeutics AG (CRSP), valued at approximately $1.31 M.

As of the Q2 2026 filing, CRISPR Therapeutics AG (CRSP) represents approximately 0.01% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.

Jefferies Group's peak holding in CRISPR Therapeutics AG (CRSP) was 24,001 shares, as reported at the end of Q2 2026.